Answers are grounded in this paper and cite their sources.
Genetic variants in CYP2D6 lead to reduced conversion of tamoxifen to the active metabolite endoxifen. However, the role of the CYP2D6 genotype in predicting tamoxifen-associated outcomes remains controversial. Accurate assignment of the CYP2D6 genotype in archival tissues is crucial for future studies attempting to determine risk prediction of outcomes in tamoxifen-treated individuals.
No takes yet. Share an insight, caveat, or question.
Bardia et al. (2010) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: